Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 11-19

  Gritsko, Tanya ^a   Williams, Ann ^a   Turkson, James ^a   Kaneko, Satoshi ^a   Bowman, Tammy ^a   Huang, Mei ^a   Nam, Sangkil ^a   Eweis, Ibrahim ^a   Diaz, Nils ^a   Sullivan, Daniel ^a   Yoder, Sean ^a   Enkemann, Steve ^a   Eschrich, Steven ^a   Lee, Ji Hyun ^a   Beam, Craig A ^a   Cheng, Jin ^a   Minton, Susan ^a   Muro Cacho, Carlos A ^a   Jove, Richard ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; INHIBITOR OF APOPTOSIS PROTEIN; STAT3 PROTEIN; SURVIVIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); STAT3 TRANSCRIPTION FACTOR;

EID: 31544458469     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1752     Document Type: Article

References (50)

1. Darnell JE. STATs and gene regulation. Science 2000;277:1630-5.
2. Levy DE, Darnell JE. STATs: transcriptional control and biologic impact. Nat Rev Mol Cell Biol 2002;3:651-62.
3. Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73.
4. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
5. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95.
6. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
7. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
8. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986;261:13754-9.
9. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
10. Biscardi JS, Ishizawar RC, Silvan CM, Parsons SJ. Tyrosine kinase signaling in breast cancer:epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000;2:203-10.
11. Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
12. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 1999;59:6145-52.
13. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
14. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
15. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000;97:4227-32.
16. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351-62.
17. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
18. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344:305-11.
19. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
20. Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998;18:2545-52.
21. Karras JG, McKay RA, Lu T, et al. STAT3 regulates the growth and immunoglobulin production of BCL (1) B cell lymphoma through control of cell cycle progression. Cell Immunol 2000;202:124-35.
22. Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ. Target gene specificity of E2F and pocket protein family members in living cells. Mol Cell Biol 2000;20:5797-807.
23. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
24. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
25. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
26. Tusher VG, Tibshirani R, Chu G. Significance analysis of miccroarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
27. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21:7611-8.
28. Seidel HM, Milocco LH, Lamb P, Darnell JE, Stein RB, Rosen J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci U S A 1995;92:3041-5.
29. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998;102:1385-92.
30. Mirza A, McGuirk M, Hocekberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
31. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.
32. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines:direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
33. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-10.
34. Xi S, Zhang Q, Dyer KF, et al. Src kinases mediate STATgrowth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003;278:31574-83.
35. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65.
36. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42.
37. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-9
38. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
39. Kanda N, Seno H, Konda Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004;23:4921-9.
40. Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59:1406-12.
41. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003;278:23130-40.
42. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23.
43. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erb B-2 and survivin genes. Cancer Lett 2001;169:155-64.
44. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54.
45. Mahboubi K, Li F, Plescia J, et al. Interleukin-11 upregulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest 2001;81:327-34.
46. Shen Y, Devgan G, Darnell JE, Bromberg JF. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-inducpd apoptosis and antagonizes the proapoptotic effects of activated Stat1 Proc Natl Acad Sci U S A 2001;98:1543-8.
47. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J Biol Chem 2001;276:45443-55.
48. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of Stat3 dimerization and biological activity. Mol Cancer Ther 2004;3:261-9.
49. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3:1533-42.
50. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.